Catégorie : Pharma

HORIANA

by jbertholdin Biotech, Institutions, Service Providers & others, Pharma

HORIANA

About the company

HORIANA is a premier consulting company dedicated to epidemiology and biostatistics, specializing in designing and conducting Healthcare Real-World Studies.

Established by a team of seasoned experts, each with over 15 years of experience in Life Sciences, Horiana is at the forefront of providing comprehensive support to its clients. With a dedicated team of more than 25 experts, Horiana is well-positioned to assist clients at every phase of their projects. Their clients span both private and public/academic healthcare professionals.

At HORIANA, they are committed to excellence and quality, ensuring the success of their clients’ projects.

About the solution

Their main solutions are:

– Expertise and Consulting: Specialized guidance in epidemiology, pharmacoepidemiology, and biostatistics/data science.
– Clinical and Observational Studies (on primary and secondary)
– Enriched Studies: Integration of data from diverse sources through multisource studies and linked studies.
– Evidence Synthesis: Conducting External Comparators such as Network Meta-Analysis (NMA) and Matching-Adjusted Indirect Comparison (MAIC).
– Synthetic Control Groups: Implementation of Synthetic Control Groups and External Control Arms.
– Training Programs: Certified QUALIOPI training center in Statistics & Epidemiology
– IDMC, DSMB and Strategic consulting

Website
Key information

–  Therapeutic areas: Biostatistics, Epidemiology & Data Science provider

–  Based in: Bordeaux, Grenoble (FRANCE) San Francisco (US)

–  Employees: 11 – 50

– Created in: 2021

RD-BIOTECH

by jbertholdin Biotech, Institutions, Service Providers & others, Pharma

RD-BIOTECH

About the company

RD-Biotech is a leading French company specialized since 2002 in the supply of plasmid DNA, recombinant antibodies, and associated fragments, as well as monoclonal antibodies and recombinant proteins.

As a global CRO/CDMO, RD-Biotech is a one-stop-shop partner in the supply of plasmid DNA (pDNA cloning & pDNA biomanufacturing) from R&D grade (discovery/preclinical) to « High Quality Grade » (phase 1/2 use in the production of ATMPs), as well as GMP grade (for phase 3 – commercial phase).

They support companies in the cell and gene therapy market (viral vectors, CAR-T, mRNA…)

About the solution

Their main competitive advantages lie on:

– Over 20 years of experience in molecular biology, engineering & biomanufacturing

– Complete offer from early discovery (pDNA cloning) to commercial manufacturing (GMP grade)

– Scalable process of pDNA production, from several mg up to 20 g, for R&D, High Quality and GMP grades

– Cost effective & adaptable process

Website
Key information

–  Therapeutic areas: Cell and Gene therapies: DNA vaccines, RNA vaccines, CAR-T cells, viral based therapies…

–  Based in: Besançon (FRANCE)

–  Employees: 11 – 50

– Created in: 2002

ROSETTA OMICS

by jbertholdin Biotech, Medtech, Pharma

ROSETTA OMICS

About the company

Rosetta Omics pioneers precision medicine through tumor characterization using spatial multiomics, deep mass spectrometry and AI. Their focus is to optimize first-line treatments by matching therapies with patients effectively, starting with liver and colon cancers. They aim to empower oncologists with a transformative tool, enhancing patient care, and cutting costs. Collaborating with pharma and biotech firms, they seek to identify new biomarkers, accelerating therapeutic and diagnostic innovations.

Committed to scientific advancement and patient well-being, Rosetta Omics is reshaping cancer care. Through cutting-edge technologies and comprehensive multiomics analysis, they provide personalized treatment insights for improved outcomes. Rosetta Omics is at the forefront of precision medicine, driven by innovation, collaboration, and a commitment to saving lives.

About the solution

Their biopsy-based predictive test can be integrated within the standard clinical procedure of biopsy collection for diagnostics to assist in the decision-making process. Their services and products can also identify biomarkers of clinical interest and be used to discover new targets for drug development.

Website
Key information

–  Therapeutic areas: Oncology, Cancer, Liver cancer, Colon cancer, Precision medicine, AI

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2023

ATLANTIC BONE SCREEN

by jbertholdin Biotech, Pharma

ATLANTIC BONE SCREEN

About the company

Atlantic Bone Screen is a French CRO providing non-GLP preclinical services.
Atlantic Bone Screen has a strong know-how in the field of osteoarticular indications / bone and joint diseases / biomaterials : inflammation & oncology & dermatology.
Atlantic Bone Screen has developed in vitro tests, in vivo animal models and benefits from robust and state-of-the-art platforms for 2D and 3D imaging, histology and histopathology.
Atlantic Bone Screen supports biotech and pharma companies to identify and characterize the therapeutic potential of their drug candidates, nutraceuticals and biomaterials through validated models and customized preclinical studies.

About the solution

Their specific expertise in bone physiology and bone diseases, cartilage and inflammatory diseases, and cancer models sets them apart from other global CROs.

Based on their internal experts and scientific network, they address their customers’ questions regarding their candidates and support them in screening, characterization, and validation of their leads to generate strong data for advancing through regulatory stages.

Additionally, their flexibility in customizing study designs, readouts, and communication and providing comprehensive reports throughout projects is highlighted as a real strength by their partners (96% of customers were either satisfied or very satisfied in the 2023 satisfaction survey).

Website
Key information

–  Therapeutic areas: Oncology, Bone Diseases, Osteoarticular Diseases, Inflammation, Dermatology, Cosmetics, Biomaterials.

–  Based in: Nantes

–  Employees: 11 – 50

– Created in: 2005

PEP-THERAPY

by jbertholdin Biotech, Pharma

PEP-THERAPY

About the company

Originally spun out from the prestigious Institut Curie and Sorbonne University (Paris, France), PEP-Therapy is a clinical-stage company developing first-in-class peptides as targeted therapies for the treatment of aggressive cancers.

Following promising Phase Ia results, including preliminary signs of efficacy, PEP-Therapy is now performing Phase Ib trials (NCT 04733027) in both Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma (PROC and PDAC).

PEP-Therapy is strongly backed by international investors: Seventure Partners, i&i Prague, Italian Angels for Growth (IAG), Doorway, Anaxago, Magna Capital Partners (MCP), BAdGE, and Majoie family.

About the solution

PEP-010, PEP-Therapy’s flagship product, in summary:
– First-in-class bifunctional targeted peptide
– MoA: triggering apoptosis by disruption of Caspase-9/PP2A interaction
– Phase Ia promising results: – Favorable safety and tolerability profiles, RP2D determined in monotherapy and in combination with paclitaxel – Promising signals of antitumor activity
– Phase Ib trials underway (NCT 04733027): multicenter (in partnership with leading clinical oncology centers: Institut Curie, Gustave Roussy)
– Focus on PROC and PDAC (Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma) in combination with paclitaxel and gemcitabine
– Indication expansion potential, in solid and in liquid cancers
– Translational biomarkers development ongoing
– Spin-off from the prestigious Institut Curie and Sorbonne University. Backed by international investors.

Website
Key information

–  Therapeutic areas: Oncology, Cancer

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2014

PERSEA

by jbertholdin Biotech, Pharma

PERSEA

About the company

Persea is a French biotech developing a game-changing treatment against liver cancers: BioTrojan.

The project originates in the encounter of 2 Inserm Researchers, Isabelle de Waziers (Phd) and Pr Philippe Beaune who had been on a reseach programm about the enzym CYP2B6 against cancer since 15 years, and of 2 MDs in Interventional Radiology: Pr Marc Sapoval (APHP, Paris) and Pr Olivier Pellerin (APHP, Paris, CMO).

Persea was founded in 2021 with 2 additional competencies: CGT industrialization (Gisèle Deblandre, Phd, CTO) and business (Sophie de Ferrières, CEO).

About the solution

BioTrojan is a Cell and Gene Therapy composed of allogeneic mesenchymal stem cells increasing the tumor sensibility to chemotheray. It destroys 100% of the tumor and induces an immune response preventing against tumor recurrence.

Competitive advantages: 1st treatment that cures hepatocarcinoma when not eligeable to surgery + protects against recurrence | industrializable with limited production costs because it is allogenic | is aimed at a large number of patients (no selection via companion test necessary) | platform approach with extension of indication to other solid cancers starting with liver metastases.

Website
Key information

–  Therapeutic areas: Solid cancers, liver cancers

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2021

OWKIN

by jbertholdin Biotech, Pharma

OWKIN

About the company

By understanding complex biology through artificial intelligence, they integrate the best of human and AI capabilities to develop improved drugs and diagnostics at scale.

Through their understanding of complex biology using AI, they identify new treatments, de-risk and accelerate clinical trials, and develop diagnostic tools to reduce time to impact for patients.

Owkin was founded with this vision in mind, combining human expertise with cutting-edge technology to revolutionize the medical field.

About the solution

Owkin works with top academic centers to curate, enrich, and generate deep, multimodal data that is AI-ready.

They apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials, and develop and deploy diagnostics in clinical practice.

Their drug discovery engines leverage their expertise in AI, biology, and medicine to understand the intricate biological interactions that define specific patient subgroups. Through their AI engines, they deliver novel drug targets and optimize drug positioning.

They combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.

Their AI diagnostics help pre-screen for biomarkers and predict outcomes — giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.

Website
Key information

–  Therapeutic areas: Oncology, Immunology and Inflammation, Cardiovascular

–  Based in: Based in Paris (FRANCE)
Offices in New York City (USA) and in London (UK)

–  Employees: 201 – 500

– Created in: 2016

AVEROA

by jbertholdin Biotech, Pharma

AVEROA

About the company


AVEROA is an emerging company with a smart business focused on the development and registration of innovative drugs with high interest for patients with strong unmet medical needs.

About the solution

Their goal is to build a strong pipeline focused on developing and registering products of high interest for patients with kidney or metabolic diseases. Their expertise lies in identifying innovative products with the potential to address significant medical needs in nephrology and advancing them to a stage of development that maximizes their therapeutic and commercial value.

Website
Key information

–  Therapeutic areas: Nephrology and Metabolism, Endocrinology

–  Based in: Grenoble (FRANCE)

–  Employees: 1 – 10

– Created in: 2021

STROMACARE

by jbertholdin Biotech, Pharma

STROMACARE

About the company


StromaCare is a biotech company specialized in discovering and developing new cancer treatments through their understanding of stromal tissue biology. They develop innovative oncology drugs, both as standalone treatments and in combination with other therapies, for treating solid tumors based on the novel approach of modulating stromal components. How cancer develops and progresses is linked to the tumor stroma. The stroma limits the efficiency of immune cells against tumor cells, facilitates the migration of tumor cells, and prevents the access of treatments to the tumor.

At StromaCare, they aim to make the stroma ‘permeable’ to immune cells and other molecules of interest to eliminate the tumor.

About the solution

StromaCare identified a set of stromal players and characterized their roles. Their lead drug candidate, STRO-501, a monoclonal antibody, targets a key stromal player called βig-h3, which is common to most cancers and serves as a novel T-cell regulator. This lead monoclonal antibody has demonstrated strong efficacy in preclinical studies, shows a favorable safety profile, and has received a favorable opinion from the EMA. StromaCare aims to start their clinical trial in 18 to 24 months, either as a standalone treatment or in combination with anti-PD1 in resistant cancers.

Their pipeline includes other targets and antibodies addressing different aspects of stromal biology.

Website
Key information

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

– Created in: 2022

EG427

by jbertholdin Biotech, Pharma

EG427

About the company

Based on their unique vector platform, EG427 delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Their vectors can achieve focal and efficient transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows for either long-term gene therapy or all-in-one gene editing approaches.

About the solution

EG427 is the second company to reach the clinical development stage with a non-replicating HSV-1 vector. They are filing a US IND and a UK CTA in early 2Q-2024 and initiating a phase 1B/2A trial to demonstrate safety and efficacy. This first product, EG110A, addresses multiple severe bladder diseases (including Neurogenic Detrusor Overactivity and Refractory Overactive Bladder) by selectively inhibiting targeted sensory neurons. It has the potential to be a major improvement over existing therapies, resulting in better care for the patients and lower costs for healthcare systems. EG110A serves a very large, unsatisfied market that nevertheless represents over $3.7B in revenues for existing therapeutic modalities.

Website
Key information

–  Therapeutic areas: Neurology, Neuro-urology

–  Based in: Headquarter and Lab: Paris (FRANCE)
Subsidiary: Boston (USA)

–  Employees: 11 – 50

– Created in: 2019